CMS grants reimbursement for single-use duodenoscope
Boston Scientific announced CMS granted a new technology add-on payment for single-use duodenoscopes applicable to the EXALT Model D Single-Use Duodenoscope as part of its Fiscal Year 2022 Hospital Inpatient Prospective Payment System.
Yearly, clinicians perform more than 700,000 endoscopic retrograde cholangiopancreatography procedures in the U.S. with approximately 1.5 million completed worldwide. The EXALT Model D Single-Use Duodenoscope was designed to eliminate the risk for infection reusable duodenoscopes are prone to. Additional reimbursement for these instruments follows the 2019 FDA recommendation to use duodenoscopes with disposable components or single-use devices when available.
“Securing New Technology Add-on Payment, in addition to transitional pass-through payment, for the EXALT Model D Duodenoscope will support health care providers in accessing this device for Medicare patients – a group that represents over 40% of all ERCPs performed in the U.S. each year," Dave Pierce, president of Boston Scientific, said in a press release. "Adequate reimbursement is key for the adoption of any new technology, and this decision from CMS will help provide hospitals with the means to treat Medicare patients with this device."
Additional device reimbursement when the EXACT Model D Single-Use Duodenoscope is used for eligible cases in an inpatient setting will begin October 1, 2021.